- Home
- CZNC vs ALT Comparison
CZNC vs ALT Comparison
Compare CZNC & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CZNC | ALT |
|---|---|---|
| Founded | 1864 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 423.4M | 421.5M |
| IPO Year | 2009 | 2005 |
Fundamental Metrics
Financial Performance| Metric | CZNC | ALT |
|---|---|---|
| Price | $25.31 | $2.85 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $23.50 | $17.67 |
| AVG Volume (30 Days) | 58.0K | ★ 3.8M |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.87% | N/A |
| EPS Growth | 7.64 | ★ 25.37 |
| EPS | ★ 0.02 | N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | $3.11 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1,271.50 | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $18.16 | $2.56 |
| 52 Week High | $25.78 | $6.44 |
Technical Indicators
Market Signals| Indicator | CZNC | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 72.95 | 47.03 |
| Support Level | $22.73 | $2.65 |
| Resistance Level | N/A | $3.09 |
| Average True Range (ATR) | 0.72 | 0.17 |
| MACD | 0.18 | -0.00 |
| Stochastic Oscillator | 86.41 | 19.64 |
Price Performance
Historical ComparisonAbout CZNC Citizens & Northern Corp
Citizens & Northern Corp is a community bank operating through its subsidiaries. It provides banking services, including deposit and loan products for personal and commercial customers. The bank also maintains a trust division that provides a wide range of financial services, such as 401(k) plans, retirement planning, estate planning, estate settlements and asset management.
About ALT Altimmune Inc.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.